Sivelestat

Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19[1][2][3][4].

Product Specifications

CAS Number

[127373-66-4]

Product Name Alternative

EI546; LY544349; ONO5046

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Elastase; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sivelestat.html

Purity

99.34

Solubility

DMSO : ≥ 100 mg/mL|Ethanol : 3.03 mg/mL (ultrasonic)

Smiles

CC(C)(C)C(OC1=CC=C(S(=O)(NC2=CC=CC=C2C(NCC(O)=O)=O)=O)C=C1)=O

Molecular Formula

C20H22N2O7S

Molecular Weight

434.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177 (2) :814-20.|[2]Yuichiro Toda, et al. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Int J Mol Med. 2007 Feb;19 (2) :237-43.|[3]Tomoharu Kono, et al. Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia-reperfusion injury in the rat bladder. Mol Cell Biochem. 2008 Apr;311 (1-2) :87-92.|[4]Adeleh Sahebnasagh, et al. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther. 2020 Aug 28.